What changed in 2026, by region posts 61–90
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Temperature-controlled material and long-haul travel is a practical problem with practical solutions, none of which are on the packaging.
Filing this under things that are true until someone shows me otherwise.
Answering the question post #60 raises rather than the one it answers.
The most useful thing anyone can add to a thin regional thread is what the official source says and where it is, rather than what happened to them.
It took me longer than it should have to see that.
Post #63 is the version of this I will quote in future. One addition.
Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.
That is a description of practice, not a recommendation of it.
Following this. I have the same question and no better information than the first post.
Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.
If this contradicts something upthread, the upthread version may well be the better one.
Regional practice around what a pharmacy will and will not do varies enormously and is not deducible from the regulatory position.
I have changed my mind on this once already, so take it as current rather than settled.
I had written a reply contradicting post #68 and deleted it. Here is what survived.
A regional experience posted here should say which year it describes. The archive keeps these permanently and they age faster than anything else on the site.
If it helps: the failure mode here is usually boring rather than dramatic.
That matches what I have seen, for whatever a single anecdote is worth.
Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.
One case, stated as one case.
Collapsed as off-topic by two members at trust level 3 or above
Temperature-controlled material and long-haul travel is a practical problem with practical solutions, none of which are on the packaging.
I keep a log of this specifically because memory is unreliable about it.
Coming back to post #72, because the follow-up matters more than the original answer.
Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).
The right answer here may simply be that it has not been measured.
Where a jurisdiction has published guidance for clinicians, that document usually answers the practical questions better than any consumer-facing page.
None of the above is medical advice and I am not qualified to give any.
Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.
The short answer was in the first line; everything after is the working.
This is the sort of exchange that makes the archive worth searching.
This follows post #81 rather than contradicting it.
Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.
Reading it again, the caveat matters more than the finding.
If a claim about your region here is out of date, correcting it with a date and a source is the single most valuable post you can make.
Everything in post #82 holds. The case it does not cover is the one I have.
The most useful thing anyone can add to a thin regional thread is what the official source says and where it is, rather than what happened to them.
It is a small point and it changes the answer, which is an awkward combination.
Both are useful and they are different contributions. A first-hand account and a citation answer different halves of the question.
Somebody will have a better source than mine, and I hope they post it.
Confirming post #87 from a second method, which matters more than confirming it from a second person.
Summaries lag badly in this area. Where a decision matters, read the current official document rather than a page about it, including this one.
Two sources, same conclusion, and I could not rule out that one copied the other.
Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).
It cost nothing to check and would have cost something not to.